English

TSCAN THERAPEUTICS, INC.

EDGAR

TCRX Current report (8-K) · filed 2026-10-16

Annual consolidated revenue for 2025: about USD 10.33M, using the latest reported figures. The previous period, 2024, was about USD 2.816M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

1.05 million USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 1051000 USD Source

Operating margin

-2,901.33%

2026 Q2 · %

Exact inputs and evidence

Operating Income: -30493000 USD Source
Revenue: 1051000 USD Source

Operating cash flow

-27.5 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -51814000 USD Source
Operating Cash Flow: -24279000 USD Source

Free cash flow

-28 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -51814000 USD Source
Operating Cash Flow: -24279000 USD Source
Capital Expenditure: 563000 USD Source
Capital Expenditure: 70000 USD Source

Cash and cash equivalents: 100 million USD 2026-06-30 Source
Exact value

100200000 USD
Long-term debt including current maturities: 32.8 million USD 2026-06-30 Source
Exact value

32779000 USD
Shares outstanding: 1.42 million shares 2021-06-30 Source
Exact value

1419819 shares

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

7.11 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Revenue: 2511000 USD · 2025-07-01 – 2025-09-30 Source
Revenue: 10325000 USD · 2025-01-01 – 2025-12-31 Source
Revenue: 7758000 USD · 2025-01-01 – 2025-09-30 Source
Revenue: 982000 USD · 2026-01-01 – 2026-03-31 Source
Revenue: 1051000 USD · 2026-04-01 – 2026-06-30 Source

Net income

-118 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -35710000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -129766000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -106789000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -28666000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -30359000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-116 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -103317000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -70853000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -135319000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -103317000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -24279000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -51814000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -24279000 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

2.16 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Capital expenditure: 4236000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 2811000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 4407000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 4236000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 70000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 563000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 70000 USD · 2026-01-01 – 2026-03-31 Source

Free cash flow

-118 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -103317000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -70853000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -135319000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -103317000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -24279000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -51814000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -24279000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 4236000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 2811000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 4407000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 4236000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 70000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 563000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 70000 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-10-16.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 6 of 11 periods available· newest 2025-12-31
Operating income: 6 of 11 periods available· newest 2025-12-31
Net income: 6 of 11 periods available· newest 2025-12-31
Operating cash flow: 6 of 11 periods available· newest 2025-12-31
Capital expenditure: 6 of 11 periods available· newest 2025-12-31
Total assets: 6 of 11 periods available· newest 2025-12-31
Total liabilities: 6 of 11 periods available· newest 2025-12-31
Current assets: 6 of 11 periods available· newest 2025-12-31
Current liabilities: 6 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 6 of 11 periods available· newest 2025-12-31
Long-term debt including current maturities: 4 of 11 periods available· newest 2025-12-31
Shares outstanding: 1 of 11 periods available· newest 2020-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+266.7%

Prior period

USD 2.82 million

2024-01-01 – 2024-12-31
Current period

USD 10.33 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

10325000 − 2816000 = 7509000 USD

2816000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
10325000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · TSCAN THERAPEUTICS, INC. · 2025-12-31 TSCAN THERAPEUTICS, INC. (edgar:1783328) Year-over-year change in Revenue: 7509000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T15:21:12Z Snapshot: 8af88d9cc91700b2fe7ebea90344fd3ba9e58046c3f90760fae54ba7e32271d7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1783328?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 10325000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1783328/000119312526089884/tcrx-20251231.htm#2053803 Filing: 000119312526089884 Input fundies:Revenue: 2816000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1783328/000119312526089884/tcrx-20251231.htm#2055453 Filing: 000119312526089884
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 2.27 million

Prior period

−USD 127.5 million

2024-01-01 – 2024-12-31
Current period

−USD 129.77 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-129766000 − -127499000 = -2267000 USD

-127499000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-129766000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · TSCAN THERAPEUTICS, INC. · 2025-12-31 TSCAN THERAPEUTICS, INC. (edgar:1783328) Year-over-year change in Net income: -2267000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T15:21:12Z Snapshot: 8af88d9cc91700b2fe7ebea90344fd3ba9e58046c3f90760fae54ba7e32271d7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1783328?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -129766000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1783328/000119312526089884/tcrx-20251231.htm#3342640 Filing: 000119312526089884 Input fundies:NetIncome: -127499000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1783328/000119312526089884/tcrx-20251231.htm#3344388 Filing: 000119312526089884
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 24.5 million

Prior period

−USD 110.82 million

2024-01-01 – 2024-12-31
Current period

−USD 135.32 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-135319000 − -110822000 = -24497000 USD

-110822000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-135319000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · TSCAN THERAPEUTICS, INC. · 2025-12-31 TSCAN THERAPEUTICS, INC. (edgar:1783328) Year-over-year change in Operating cash flow: -24497000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T15:21:12Z Snapshot: 8af88d9cc91700b2fe7ebea90344fd3ba9e58046c3f90760fae54ba7e32271d7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1783328?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -135319000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1783328/000119312526089884/tcrx-20251231.htm#2415523 Filing: 000119312526089884 Input fundies:OperatingCashFlow: -110822000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1783328/000119312526089884/tcrx-20251231.htm#2417376 Filing: 000119312526089884
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+15.2%

Prior period

USD 3.83 million

2024-01-01 – 2024-12-31
Current period

USD 4.41 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

4407000 − 3825000 = 582000 USD

3825000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
4407000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · TSCAN THERAPEUTICS, INC. · 2025-12-31 TSCAN THERAPEUTICS, INC. (edgar:1783328) Year-over-year change in Capital expenditure: 582000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T15:21:12Z Snapshot: 8af88d9cc91700b2fe7ebea90344fd3ba9e58046c3f90760fae54ba7e32271d7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1783328?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 4407000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1783328/000119312526089884/tcrx-20251231.htm#2422102 Filing: 000119312526089884 Input fundies:CapitalExpenditure: 3825000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1783328/000119312526089884/tcrx-20251231.htm#2423840 Filing: 000119312526089884
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 10.33 million 100% of revenue
Operating costs Derived USD 146.14 million 1,415% of revenue
Operating income −USD 135.81 million −1,315% of revenue
Tax, interest and other Derived −USD 6.05 million −59% of revenue
Net income −USD 129.77 million −1,257% of revenue

Cash

Operating cash flow −USD 135.32 million −1,311% of revenue
Capital expenditure USD 4.41 million 43% of revenue
Free cash flow Derived −USD 139.73 million −1,353% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2020 Operating loss: operating costs were 2,518% of revenue.
2021 Operating loss: operating costs were 580% of revenue.
2022 Operating loss: operating costs were 592% of revenue.
2023 Operating loss: operating costs were 544% of revenue.
2024 Operating loss: operating costs were 4,888% of revenue.
2025 Operating loss: operating costs were 1,415% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2020 2020-01-01 – 2020-12-31	1085000	27318000 Derived	-26233000	-106000 Derived	-26127000	-7261000 Derived	Source 2020-01-01 – 2020-12-31: 1085000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -26233000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -26127000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -3023000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 4238000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	10141000	58782000 Derived	-48641000	-16000 Derived	-48625000	-58618000 Derived	Source 2021-01-01 – 2021-12-31: 10141000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -48641000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -48625000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -48677000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 9941000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	13535000	80171000 Derived	-66636000	-415000 Derived	-66221000	-70728000 Derived	Source 2022-01-01 – 2022-12-31: 13535000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -66636000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -66221000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -66503000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 4225000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	21049000	114507000 Derived	-93458000	-4240000 Derived	-89218000	-64504000 Derived	Source 2023-01-01 – 2023-12-31: 21049000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -93458000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -89218000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -61358000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 3146000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	2816000	137637000 Derived	-134821000	-7322000 Derived	-127499000	-114647000 Derived	Source 2024-01-01 – 2024-12-31: 2816000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -134821000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -127499000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -110822000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 3825000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	10325000	146138000 Derived	-135813000	-6047000 Derived	-129766000	-139726000 Derived	Source 2025-01-01 – 2025-12-31: 10325000 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -135813000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -129766000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -135319000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 4407000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 10.3M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Revenue	1085000	Revenue: 1085000 Open source
20212021-12-31	Revenue	10141000	Revenue: 10141000 Open source
20222022-12-31	Revenue	13535000	Revenue: 13535000 Open source
20232023-12-31	Revenue	21049000	Revenue: 21049000 Open source
20242024-12-31	Revenue	2816000	Revenue: 2816000 Open source
20252025-12-31	Revenue	10325000	Revenue: 10325000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

266.7% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Year over year	No prior comparable period	Revenue: 1085000 Open source
20212021-12-31	Year over year	834.7%	Revenue: 10141000 Open source Revenue: 1085000 Open source
20222022-12-31	Year over year	33.5%	Revenue: 13535000 Open source Revenue: 10141000 Open source
20232023-12-31	Year over year	55.5%	Revenue: 21049000 Open source Revenue: 13535000 Open source
20242024-12-31	Year over year	-86.6%	Revenue: 2816000 Open source Revenue: 21049000 Open source
20252025-12-31	Year over year	266.7%	Revenue: 10325000 Open source Revenue: 2816000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -1,315.4% 2025

Net margin -1,256.8% 2025

Free cash flow margin -1,353.3% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Operating margin	-2,417.8%	Operating Income: -26233000 Open source Revenue: 1085000 Open source
20212021-12-31	Operating margin	-479.6%	Operating Income: -48641000 Open source Revenue: 10141000 Open source
20222022-12-31	Operating margin	-492.3%	Operating Income: -66636000 Open source Revenue: 13535000 Open source
20232023-12-31	Operating margin	-444%	Operating Income: -93458000 Open source Revenue: 21049000 Open source
20242024-12-31	Operating margin	-4,787.7%	Operating Income: -134821000 Open source Revenue: 2816000 Open source
20252025-12-31	Operating margin	-1,315.4%	Operating Income: -135813000 Open source Revenue: 10325000 Open source
20202020-12-31	Net margin	-2,408%	Net Income: -26127000 Open source Revenue: 1085000 Open source
20212021-12-31	Net margin	-479.5%	Net Income: -48625000 Open source Revenue: 10141000 Open source
20222022-12-31	Net margin	-489.3%	Net Income: -66221000 Open source Revenue: 13535000 Open source
20232023-12-31	Net margin	-423.9%	Net Income: -89218000 Open source Revenue: 21049000 Open source
20242024-12-31	Net margin	-4,527.7%	Net Income: -127499000 Open source Revenue: 2816000 Open source
20252025-12-31	Net margin	-1,256.8%	Net Income: -129766000 Open source Revenue: 10325000 Open source
20202020-12-31	Free cash flow margin	-669.2%	Revenue: 1085000 Open source Operating Cash Flow: -3023000 Open source Capital Expenditure: 4238000 Open source
20212021-12-31	Free cash flow margin	-578%	Revenue: 10141000 Open source Operating Cash Flow: -48677000 Open source Capital Expenditure: 9941000 Open source
20222022-12-31	Free cash flow margin	-522.6%	Revenue: 13535000 Open source Operating Cash Flow: -66503000 Open source Capital Expenditure: 4225000 Open source
20232023-12-31	Free cash flow margin	-306.4%	Revenue: 21049000 Open source Operating Cash Flow: -61358000 Open source Capital Expenditure: 3146000 Open source
20242024-12-31	Free cash flow margin	-4,071.3%	Revenue: 2816000 Open source Operating Cash Flow: -110822000 Open source Capital Expenditure: 3825000 Open source
20252025-12-31	Free cash flow margin	-1,353.3%	Revenue: 10325000 Open source Operating Cash Flow: -135319000 Open source Capital Expenditure: 4407000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -135.3M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Operating cash flow	-3023000	Operating Cash Flow: -3023000 Open source
20212021-12-31	Operating cash flow	-48677000	Operating Cash Flow: -48677000 Open source
20222022-12-31	Operating cash flow	-66503000	Operating Cash Flow: -66503000 Open source
20232023-12-31	Operating cash flow	-61358000	Operating Cash Flow: -61358000 Open source
20242024-12-31	Operating cash flow	-110822000	Operating Cash Flow: -110822000 Open source
20252025-12-31	Operating cash flow	-135319000	Operating Cash Flow: -135319000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -139.7M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Free cash flow	-7261000	Operating Cash Flow: -3023000 Open source Capital Expenditure: 4238000 Open source
20212021-12-31	Free cash flow	-58618000	Operating Cash Flow: -48677000 Open source Capital Expenditure: 9941000 Open source
20222022-12-31	Free cash flow	-70728000	Operating Cash Flow: -66503000 Open source Capital Expenditure: 4225000 Open source
20232023-12-31	Free cash flow	-64504000	Operating Cash Flow: -61358000 Open source Capital Expenditure: 3146000 Open source
20242024-12-31	Free cash flow	-114647000	Operating Cash Flow: -110822000 Open source Capital Expenditure: 3825000 Open source
20252025-12-31	Free cash flow	-139726000	Operating Cash Flow: -135319000 Open source Capital Expenditure: 4407000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

46.2% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Liabilities / assets	65.4%	Total Liabilities: 32519000 Open source Total Assets: 49738000 Open source
20212021-12-31	Liabilities / assets	14.5%	Total Liabilities: 27329000 Open source Total Assets: 188107000 Open source
20222022-12-31	Liabilities / assets	50.1%	Total Liabilities: 99657000 Open source Total Assets: 199091000 Open source
20232023-12-31	Liabilities / assets	44.6%	Total Liabilities: 121282000 Open source Total Assets: 272149000 Open source
20242024-12-31	Liabilities / assets	35.1%	Total Liabilities: 130148000 Open source Total Assets: 371118000 Open source
20252025-12-31	Liabilities / assets	46.2%	Total Liabilities: 105666000 Open source Total Assets: 228789000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

8.41× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Current assets / current liabilities	2.09×	Current Assets: 36445000 Open source Current Liabilities: 17446000 Open source
20212021-12-31	Current assets / current liabilities	7.76×	Current Assets: 165654000 Open source Current Liabilities: 21343000 Open source
20222022-12-31	Current assets / current liabilities	7.17×	Current Assets: 124127000 Open source Current Liabilities: 17305000 Open source
20232023-12-31	Current assets / current liabilities	6.51×	Current Assets: 194237000 Open source Current Liabilities: 29820000 Open source
20242024-12-31	Current assets / current liabilities	8.14×	Current Assets: 292722000 Open source Current Liabilities: 35956000 Open source
20252025-12-31	Current assets / current liabilities	8.41×	Current Assets: 157208000 Open source Current Liabilities: 18695000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2020 2020-01-01 – 2020-12-31	−USD 26.13 million Exact value Exact value: -26127000 USD 2020-01-01 – 2020-12-31: -26127000 USD Inspect Net Income Open source Share or cite Citation for Net Income · TSCAN THERAPEUTICS, INC. · 2020-12-31 TSCAN THERAPEUTICS, INC. (edgar:1783328) Net Income: -26127000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T15:21:12Z Snapshot: 8af88d9cc91700b2fe7ebea90344fd3ba9e58046c3f90760fae54ba7e32271d7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1783328/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -26127000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1783328/000095017022003175/tcrx-20211231.htm#3332112 Filing: 000095017022003175 The citation records this snapshot. The page link may show a newer release later.	−USD 3.02 million Exact value Exact value: -3023000 USD 2020-01-01 – 2020-12-31: -3023000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TSCAN THERAPEUTICS, INC. · 2020-12-31 TSCAN THERAPEUTICS, INC. (edgar:1783328) Operating Cash Flow: -3023000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T15:21:12Z Snapshot: 8af88d9cc91700b2fe7ebea90344fd3ba9e58046c3f90760fae54ba7e32271d7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1783328/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -3023000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1783328/000095017022003175/tcrx-20211231.htm#2558160 Filing: 000095017022003175 The citation records this snapshot. The page link may show a newer release later.	USD 4.24 million Exact value Exact value: 4238000 USD 2020-01-01 – 2020-12-31: 4238000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TSCAN THERAPEUTICS, INC. · 2020-12-31 TSCAN THERAPEUTICS, INC. (edgar:1783328) Capital Expenditure: 4238000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T15:21:12Z Snapshot: 8af88d9cc91700b2fe7ebea90344fd3ba9e58046c3f90760fae54ba7e32271d7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1783328/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 4238000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1783328/000095017022003175/tcrx-20211231.htm#2565499 Filing: 000095017022003175 The citation records this snapshot. The page link may show a newer release later.	−USD 7.26 million Calculation and evidence -3023000 − 4238000 USD Exact free cash flow: -7261000 USD 2020-01-01 – 2020-12-31: -3023000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 4238000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TSCAN THERAPEUTICS, INC. · 2020-12-31 TSCAN THERAPEUTICS, INC. (edgar:1783328) Free cash flow: -7261000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T15:21:12Z Snapshot: 8af88d9cc91700b2fe7ebea90344fd3ba9e58046c3f90760fae54ba7e32271d7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1783328?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -3023000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1783328/000095017022003175/tcrx-20211231.htm#2558160 Filing: 000095017022003175 Input fundies:CapitalExpenditure: 4238000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1783328/000095017022003175/tcrx-20211231.htm#2565499 Filing: 000095017022003175 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 48.63 million Exact value Exact value: -48625000 USD 2021-01-01 – 2021-12-31: -48625000 USD Inspect Net Income Open source Share or cite Citation for Net Income · TSCAN THERAPEUTICS, INC. · 2021-12-31 TSCAN THERAPEUTICS, INC. (edgar:1783328) Net Income: -48625000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T15:21:12Z Snapshot: 8af88d9cc91700b2fe7ebea90344fd3ba9e58046c3f90760fae54ba7e32271d7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1783328/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -48625000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1783328/000095017023006589/tcrx-20221231.htm#3591636 Filing: 000095017023006589 The citation records this snapshot. The page link may show a newer release later.	−USD 48.68 million Exact value Exact value: -48677000 USD 2021-01-01 – 2021-12-31: -48677000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TSCAN THERAPEUTICS, INC. · 2021-12-31 TSCAN THERAPEUTICS, INC. (edgar:1783328) Operating Cash Flow: -48677000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T15:21:12Z Snapshot: 8af88d9cc91700b2fe7ebea90344fd3ba9e58046c3f90760fae54ba7e32271d7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1783328/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -48677000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1783328/000095017023006589/tcrx-20221231.htm#2737366 Filing: 000095017023006589 The citation records this snapshot. The page link may show a newer release later.	USD 9.94 million Exact value Exact value: 9941000 USD 2021-01-01 – 2021-12-31: 9941000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TSCAN THERAPEUTICS, INC. · 2021-12-31 TSCAN THERAPEUTICS, INC. (edgar:1783328) Capital Expenditure: 9941000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T15:21:12Z Snapshot: 8af88d9cc91700b2fe7ebea90344fd3ba9e58046c3f90760fae54ba7e32271d7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1783328/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 9941000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1783328/000095017023006589/tcrx-20221231.htm#2745484 Filing: 000095017023006589 The citation records this snapshot. The page link may show a newer release later.	−USD 58.62 million Calculation and evidence -48677000 − 9941000 USD Exact free cash flow: -58618000 USD 2021-01-01 – 2021-12-31: -48677000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 9941000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TSCAN THERAPEUTICS, INC. · 2021-12-31 TSCAN THERAPEUTICS, INC. (edgar:1783328) Free cash flow: -58618000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T15:21:12Z Snapshot: 8af88d9cc91700b2fe7ebea90344fd3ba9e58046c3f90760fae54ba7e32271d7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1783328?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -48677000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1783328/000095017023006589/tcrx-20221231.htm#2737366 Filing: 000095017023006589 Input fundies:CapitalExpenditure: 9941000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1783328/000095017023006589/tcrx-20221231.htm#2745484 Filing: 000095017023006589 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 66.22 million Exact value Exact value: -66221000 USD 2022-01-01 – 2022-12-31: -66221000 USD Inspect Net Income Open source Share or cite Citation for Net Income · TSCAN THERAPEUTICS, INC. · 2022-12-31 TSCAN THERAPEUTICS, INC. (edgar:1783328) Net Income: -66221000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T15:21:12Z Snapshot: 8af88d9cc91700b2fe7ebea90344fd3ba9e58046c3f90760fae54ba7e32271d7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1783328/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -66221000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1783328/000095017024026875/tcrx-20231231.htm#2707210 Filing: 000095017024026875 The citation records this snapshot. The page link may show a newer release later.	−USD 66.5 million Exact value Exact value: -66503000 USD 2022-01-01 – 2022-12-31: -66503000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TSCAN THERAPEUTICS, INC. · 2022-12-31 TSCAN THERAPEUTICS, INC. (edgar:1783328) Operating Cash Flow: -66503000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T15:21:12Z Snapshot: 8af88d9cc91700b2fe7ebea90344fd3ba9e58046c3f90760fae54ba7e32271d7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1783328/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -66503000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1783328/000095017024026875/tcrx-20231231.htm#2108977 Filing: 000095017024026875 The citation records this snapshot. The page link may show a newer release later.	USD 4.23 million Exact value Exact value: 4225000 USD 2022-01-01 – 2022-12-31: 4225000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TSCAN THERAPEUTICS, INC. · 2022-12-31 TSCAN THERAPEUTICS, INC. (edgar:1783328) Capital Expenditure: 4225000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T15:21:12Z Snapshot: 8af88d9cc91700b2fe7ebea90344fd3ba9e58046c3f90760fae54ba7e32271d7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1783328/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 4225000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1783328/000095017024026875/tcrx-20231231.htm#2113750 Filing: 000095017024026875 The citation records this snapshot. The page link may show a newer release later.	−USD 70.73 million Calculation and evidence -66503000 − 4225000 USD Exact free cash flow: -70728000 USD 2022-01-01 – 2022-12-31: -66503000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 4225000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TSCAN THERAPEUTICS, INC. · 2022-12-31 TSCAN THERAPEUTICS, INC. (edgar:1783328) Free cash flow: -70728000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T15:21:12Z Snapshot: 8af88d9cc91700b2fe7ebea90344fd3ba9e58046c3f90760fae54ba7e32271d7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1783328?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -66503000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1783328/000095017024026875/tcrx-20231231.htm#2108977 Filing: 000095017024026875 Input fundies:CapitalExpenditure: 4225000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1783328/000095017024026875/tcrx-20231231.htm#2113750 Filing: 000095017024026875 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 89.22 million Exact value Exact value: -89218000 USD 2023-01-01 – 2023-12-31: -89218000 USD Inspect Net Income Open source Share or cite Citation for Net Income · TSCAN THERAPEUTICS, INC. · 2023-12-31 TSCAN THERAPEUTICS, INC. (edgar:1783328) Net Income: -89218000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T15:21:12Z Snapshot: 8af88d9cc91700b2fe7ebea90344fd3ba9e58046c3f90760fae54ba7e32271d7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1783328/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -89218000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1783328/000095017025033077/tcrx-20241231.htm#3836024 Filing: 000095017025033077 The citation records this snapshot. The page link may show a newer release later.	−USD 61.36 million Exact value Exact value: -61358000 USD 2023-01-01 – 2023-12-31: -61358000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TSCAN THERAPEUTICS, INC. · 2023-12-31 TSCAN THERAPEUTICS, INC. (edgar:1783328) Operating Cash Flow: -61358000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T15:21:12Z Snapshot: 8af88d9cc91700b2fe7ebea90344fd3ba9e58046c3f90760fae54ba7e32271d7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1783328/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -61358000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1783328/000095017025033077/tcrx-20241231.htm#3005994 Filing: 000095017025033077 The citation records this snapshot. The page link may show a newer release later.	USD 3.15 million Exact value Exact value: 3146000 USD 2023-01-01 – 2023-12-31: 3146000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TSCAN THERAPEUTICS, INC. · 2023-12-31 TSCAN THERAPEUTICS, INC. (edgar:1783328) Capital Expenditure: 3146000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T15:21:12Z Snapshot: 8af88d9cc91700b2fe7ebea90344fd3ba9e58046c3f90760fae54ba7e32271d7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1783328/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3146000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1783328/000095017025033077/tcrx-20241231.htm#3012035 Filing: 000095017025033077 The citation records this snapshot. The page link may show a newer release later.	−USD 64.5 million Calculation and evidence -61358000 − 3146000 USD Exact free cash flow: -64504000 USD 2023-01-01 – 2023-12-31: -61358000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 3146000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TSCAN THERAPEUTICS, INC. · 2023-12-31 TSCAN THERAPEUTICS, INC. (edgar:1783328) Free cash flow: -64504000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T15:21:12Z Snapshot: 8af88d9cc91700b2fe7ebea90344fd3ba9e58046c3f90760fae54ba7e32271d7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1783328?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -61358000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1783328/000095017025033077/tcrx-20241231.htm#3005994 Filing: 000095017025033077 Input fundies:CapitalExpenditure: 3146000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1783328/000095017025033077/tcrx-20241231.htm#3012035 Filing: 000095017025033077 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 127.5 million Exact value Exact value: -127499000 USD 2024-01-01 – 2024-12-31: -127499000 USD Inspect Net Income Open source Share or cite Citation for Net Income · TSCAN THERAPEUTICS, INC. · 2024-12-31 TSCAN THERAPEUTICS, INC. (edgar:1783328) Net Income: -127499000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T15:21:12Z Snapshot: 8af88d9cc91700b2fe7ebea90344fd3ba9e58046c3f90760fae54ba7e32271d7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1783328/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -127499000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1783328/000119312526089884/tcrx-20251231.htm#3344388 Filing: 000119312526089884 The citation records this snapshot. The page link may show a newer release later.	−USD 110.82 million Exact value Exact value: -110822000 USD 2024-01-01 – 2024-12-31: -110822000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TSCAN THERAPEUTICS, INC. · 2024-12-31 TSCAN THERAPEUTICS, INC. (edgar:1783328) Operating Cash Flow: -110822000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T15:21:12Z Snapshot: 8af88d9cc91700b2fe7ebea90344fd3ba9e58046c3f90760fae54ba7e32271d7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1783328/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -110822000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1783328/000119312526089884/tcrx-20251231.htm#2417376 Filing: 000119312526089884 The citation records this snapshot. The page link may show a newer release later.	USD 3.83 million Exact value Exact value: 3825000 USD 2024-01-01 – 2024-12-31: 3825000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TSCAN THERAPEUTICS, INC. · 2024-12-31 TSCAN THERAPEUTICS, INC. (edgar:1783328) Capital Expenditure: 3825000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T15:21:12Z Snapshot: 8af88d9cc91700b2fe7ebea90344fd3ba9e58046c3f90760fae54ba7e32271d7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1783328/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3825000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1783328/000119312526089884/tcrx-20251231.htm#2423840 Filing: 000119312526089884 The citation records this snapshot. The page link may show a newer release later.	−USD 114.65 million Calculation and evidence -110822000 − 3825000 USD Exact free cash flow: -114647000 USD 2024-01-01 – 2024-12-31: -110822000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 3825000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TSCAN THERAPEUTICS, INC. · 2024-12-31 TSCAN THERAPEUTICS, INC. (edgar:1783328) Free cash flow: -114647000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T15:21:12Z Snapshot: 8af88d9cc91700b2fe7ebea90344fd3ba9e58046c3f90760fae54ba7e32271d7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1783328?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -110822000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1783328/000119312526089884/tcrx-20251231.htm#2417376 Filing: 000119312526089884 Input fundies:CapitalExpenditure: 3825000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1783328/000119312526089884/tcrx-20251231.htm#2423840 Filing: 000119312526089884 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 129.77 million Exact value Exact value: -129766000 USD 2025-01-01 – 2025-12-31: -129766000 USD Inspect Net Income Open source Share or cite Citation for Net Income · TSCAN THERAPEUTICS, INC. · 2025-12-31 TSCAN THERAPEUTICS, INC. (edgar:1783328) Net Income: -129766000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T15:21:12Z Snapshot: 8af88d9cc91700b2fe7ebea90344fd3ba9e58046c3f90760fae54ba7e32271d7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1783328/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -129766000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1783328/000119312526089884/tcrx-20251231.htm#3342640 Filing: 000119312526089884 The citation records this snapshot. The page link may show a newer release later.	−USD 135.32 million Exact value Exact value: -135319000 USD 2025-01-01 – 2025-12-31: -135319000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TSCAN THERAPEUTICS, INC. · 2025-12-31 TSCAN THERAPEUTICS, INC. (edgar:1783328) Operating Cash Flow: -135319000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T15:21:12Z Snapshot: 8af88d9cc91700b2fe7ebea90344fd3ba9e58046c3f90760fae54ba7e32271d7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1783328/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -135319000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1783328/000119312526089884/tcrx-20251231.htm#2415523 Filing: 000119312526089884 The citation records this snapshot. The page link may show a newer release later.	USD 4.41 million Exact value Exact value: 4407000 USD 2025-01-01 – 2025-12-31: 4407000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TSCAN THERAPEUTICS, INC. · 2025-12-31 TSCAN THERAPEUTICS, INC. (edgar:1783328) Capital Expenditure: 4407000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T15:21:12Z Snapshot: 8af88d9cc91700b2fe7ebea90344fd3ba9e58046c3f90760fae54ba7e32271d7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1783328/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 4407000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1783328/000119312526089884/tcrx-20251231.htm#2422102 Filing: 000119312526089884 The citation records this snapshot. The page link may show a newer release later.	−USD 139.73 million Calculation and evidence -135319000 − 4407000 USD Exact free cash flow: -139726000 USD 2025-01-01 – 2025-12-31: -135319000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 4407000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TSCAN THERAPEUTICS, INC. · 2025-12-31 TSCAN THERAPEUTICS, INC. (edgar:1783328) Free cash flow: -139726000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T15:21:12Z Snapshot: 8af88d9cc91700b2fe7ebea90344fd3ba9e58046c3f90760fae54ba7e32271d7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1783328?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -135319000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1783328/000119312526089884/tcrx-20251231.htm#2415523 Filing: 000119312526089884 Input fundies:CapitalExpenditure: 4407000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1783328/000119312526089884/tcrx-20251231.htm#2422102 Filing: 000119312526089884 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

29 filings · 1,443 latest values · 1,443 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001783328, 1783328, TCRX, edgar:1783328

Also known as TSCAN THERAPEUTICS, INC., TScan Therapeutics, Inc.

TSCAN THERAPEUTICS, INC.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation